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Legislative Mandate 
 
The following report is hereby issued pursuant to Section 25A of Chapter 112 of the 
Massachusetts General Laws, as inserted by Chapter 159 of the Acts of 2014, as follows:  
 
Section 25A. The board shall submit an annual report to the department of public health, the joint 
committee on public health and the joint committee on health care financing on or before 
December 31. The report shall detail the investigatory and disciplinary actions conducted by the 
board and shall detail: (1) each Complaint received by the board or initiated by the board; (2) the 
date of the Complaint; (3) the violation alleged; (4) the name of any state or federal agency that 
collaborated with the Investigation; (5) the summary of the final decision of the board to: (i) 
dismiss the Complaint, (ii) impose an informal sanction or penalty, (iii) impose a formal sanction 
or penalty or (iv) amend a previously issued sanction or penalty; and (6) whether the board 
reported the result of its Investigation to another state board, federal agency or external entity. 
 
All relevant data collected and analyzed under subsections (b) to (e), inclusive, of section 39D 
shall be summarized and included in the report. The report shall be made available, including by 
electronic means, to the public and all hospitals, pharmacies and health care providers doing 
business in the commonwealth. Said report shall be posted on the department of public health's 
website. 
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Executive Summary 
 
The enactment of Chapter 159 of the Acts of 2014, An Act Relative to Pharmacy Practice in the 
Commonwealth, brought with it many new requirements and opportunities for the Board of 
Registration in Pharmacy (Board). This Report, entitled “Investigatory & Disciplinary Actions 
Conducted by the Board of Registration in Pharmacy” is intended to track all Complaints that 
moved through the Board from December 1, 2016 to December 1, 2017.  This is the fifth annual 
Report as directed by the Act. 
 
Each year the Board must track and report (1) each Complaint received by the Board or initiated 
by the Board; (2) the date of the Complaint; (3) the violation alleged; (4) the name of any state or 
federal agency that collaborated with the Investigation; (5) the summary of the final decision of 
the Board to: (i) dismiss the Complaint, (ii) impose an informal sanction or penalty, (iii) impose 
a formal sanction or penalty or (iv) amend a previously issued sanction or penalty; and (6) 
whether the Board reported the result of its Investigation to another state board, federal agency or 
external entity.  
 
The Board and Board staff have continued to work diligently to conduct Investigations and 
process cases expeditiously.  In 2017, much progress has been made including the following: 
 
 The continued expedited processing of files; 
 The continued heightened monitoring of drug losses and other drug violations resulting in 
an increase of Complaints resulting in discipline; 
 An increase in dismissed Complaints due to the continued implementation of Just Culture 
through the use of voluntary anticipatory continuing education credits in lieu of discipline 
for specified Complaint types; 
 The continued collaboration with local, state and federal agencies; 
 A continued robust field presence uncovering regulatory violations and inspectional 
deficiencies; and 
 A continued focus on information gathering at the Investigation level prior to initiating 
formal Complaints. 
 
Since the first annual Report in 2013, the processes put in place have allowed the Board and 
Board staff to move cases through the system at an accelerated pace.  A thorough Investigation 
and well written report allows the Board to resolve these cases quickly.  The goal is to continue 
to fine-tune the Board’s processes and procedures and ensure that quality improvement is 
monitored, continuing in 2018 and beyond. 
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Introduction 
 
Following the 2012 multi-state meningitis outbreak that was attributed to products from a 
Massachusetts-based pharmacy, legislation containing sweeping pharmacy practice reform was 
signed into law. Immediately after the outbreak, the Board began implementing regulatory and 
administrative reforms to improve oversight of the compounding pharmacy industry. 
Specifically, the Board staff instituted new or updated existing administrative procedures, 
including priorities for Complaint Investigations; timelines and guidelines for standard 
Investigation activities; guidelines for handling evidence and chain of custody logs; and 
processes for Complaint intake and triage. Additionally, Board staff developed new policies and 
procedures, including managing communication about abnormal test results; managing above 
action limit
1
 environmental monitoring results; pharmacy retail drug store closures; and handling 
incoming reports of theft or loss of controlled substances. These efforts helped the Board achieve 
its goal of enhanced oversight of the compounding pharmacy industry, as well as traditional 
retail pharmacies. 
 
This annual report tracks all pharmacy Complaints that were either pending, received, initiated, 
or opened during the period of December 1, 2016 through December 1, 2017. 
 
  
                                                 
1 The level which requires a pharmacy engaged in sterile compounding to take remedial measures. 
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Case Flow Overview 
An overview of the Board’s case flow is provided to offer context to this report.2 The Board 
receives initial Complaints alleging regulatory violations or other misconduct against a licensee. 
At a weekly pharmacy triage meeting, Board staff determines whether the allegations, if true, 
assert a violation of laws or regulations governing the practice of pharmacy by the particular 
licensee, and take one of three actions: 
1. If they determine that the facts alleged, if true, would not constitute a violation, Board staff 
will close the matter. 
2. If they determine that the facts alleged do constitute a violation and that there is clear 
evidence supporting the allegations, Board staff open a formal disciplinary Complaint 
(Complaint). 
3. If further information is needed to make the determination, Board staff open an Investigation. 
 
In the case of both Complaints and Investigations, Board staff conducts further investigation as 
necessary. If the evidence gathered in an Investigation clearly supports a violation, the 
Investigation may be immediately converted into a Complaint. If the Investigation does not yield 
clear evidence supporting a violation against a particular licensee, the Investigation is presented 
to the Board to determine if a Complaint should be opened or the matter should be closed. 
 
As part of the Investigation, the investigator contacts the licensee for a response to the 
allegations. The investigators also obtain evidence, as available, from complainants
3
 and other 
witnesses. When the Investigation is complete, the investigator writes a report. The report is then 
reviewed by the Director of Pharmacy Investigations to ensure accuracy and completeness. 
 
Next, the Director of Pharmacy Investigations determines whether the Complaint will be 
presented to the Board or go to the Board Delegated Complaint Review (BDCR) committee.
4
  
The BDCR has authority to dispose of Investigations or Complaints that fall under Board-
specified criteria. 
 
If the Complaint is outside of the BDCR criteria, the Complaint will be slotted for review on a 
Board meeting agenda and subsequently presented to the Board. Following the Board meeting 
review, the Board members may take the following actions: (1) dismiss the matter; (2) request 
further Investigation; (3) authorize commencement of disciplinary proceedings; and/or (4) 
authorize terms for resolution of the Complaint by consent agreement. 
 
In reviewing the data presented in Appendices B, C, and D, you will notice that the length of 
Investigation and length of time until resolution of these cases may vary considerably. Various 
factors may contribute to the length of a case including complexity; availability of evidence or 
witnesses; concurrent criminal matters where Board cases may be delayed or placed on hold; 
lengthy administrative hearings; appeal of final decisions. Appendices E through Q summarize 
relevant information captured in the overall data.  
                                                 
2
 See Appendix A:  Case Flow Diagram. 
3
 Complainant: a person who makes a formal charge in an administrative proceeding or court saying that someone 
has done something wrong. 
4
 The BDCR consists of at least one Board member and at least the following Board staff: (1) the Executive Director 
or their designee; (2) Director of Compliance or their designee; and (3) Board Counsel. 
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Data Structure 
The data are separated into three (3) sections: 
1. Formal Complaints; 
2. Investigations; and 
3. Preventable Medication Errors. 
 
For all cases listed, the report indicates the number assigned to each case, the name and license 
number of the licensees involved, the violation alleged,
5
 and, if the case is beyond the 
Investigation stage, the name of any local, state or federal agency that collaborated in the 
Investigation. For each of the cases handled by the Board during the above-listed time frame, a 
chronological account of the Board actions taken is indicated as follows: 
 
 For Complaints, the date the Investigation was opened, the date it was sent to the Board 
for Board action, the date it went to Board Counsel, the date it was sent to Prosecution, 
and the date the case was closed are included.  
o If the case is closed, the result is provided.  
o If the result was discipline on a license, the report indicates if the discipline was 
externally reported.  
o If a “not applicable (N/A)” is noted, it indicates that the Investigation or 
Complaint did not proceed to that stage or does not yet have a final decision. 
 
 For Investigations, the date the Investigation was opened, the date it was closed, and the 
date any Complaint was opened as a result of the Investigation are included. Associated 
Complaints that are related, but opened prior to the Investigation or in relation to the 
Investigation are also included in this report. An Investigation cannot result in discipline, 
because it would first have to be converted to a Complaint, and for that reason, no results 
of Investigations have been reported externally. 
 
 The report of Preventable Medication Errors details all available information for 
Complaints and Investigations where the alleged violation was related to a medication 
error. For each medication error, the report indicates a synopsis of the medication error.  
Redundant errors are typically companion cases related to the same medication error, for 
all responsible licensees (pharmacy, pharmacist, pharmacy intern, pharmacy technician, 
etc.) 
 
This Report is comprised primarily of data that has been collected and analyzed from December 
1, 2016 through December 1, 2017. The data presented in the Excel spreadsheets in Appendices 
B, C, and D contain all of the information that has been collected. Appendices E through Q 
contain an analysis of the information as well as charts to show a quick examination of the data, 
easily compare data sets and emphasize trends. 
  
                                                 
5
 Violations marked “Serious Reportable Event” pertains to a pharmacy’s requirement to report to the Board any 
improper dispensing of a prescription drug that results in serious injury or death. Violations marked “Other” are 
instances that do not fall under typical categories in the licensure database. Each year, the files in this category are 
reviewed to determine if new categories need to be established. 
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Conclusion 
 
The systematic changes and improvements that have been put in place over the last five years 
reflect a Board that has policies and procedures that are clear, effective, and efficient. In 
addition, these changes also support a group of pharmacy investigators that continue to have a 
commanding field presence which they utilize to educate the pharmacy community on 
compliance standards, ultimately leading to improved compliance with pharmacy laws and 
regulations. 
 
This report details all formal Complaints and Investigations that were pending, received, 
initiated, or opened by the Board during the period of December 1, 2016 through December 1, 
2017. Significant progress has been made, including the following: 
 
 In 2017, Board staff continued the efficient processing system established in 2014. 
Overall, the data depict that the high rate of case closures established in 2014 was 
maintained in 2017, despite the rise of opening volume. 
 The Board continued to process cases expeditiously in 2017, resulting in a 130.4% 
increase in case closures since 2013. 
 Board staff continued to encourage self-reports of continuing education deficiencies 
(classified as “Regulatory Violations”), resulting in an increase in Investigations and 
related to these events. 
 Investigators continue to pay close attention to the reports of drug losses, record keeping 
discrepancies and diversions, resulting in an increase of “Drug Violations” Complaints 
and surpassing the volume of the historical leader, “Failure to Fill RX Properly” 
Complaints. 
 A continued field presence in 2017 uncovered regulatory violations and inspectional 
deficiencies resulting in formal Complaints.   
 The Board and staff continue to forge strong relationships with our local, state and 
federal partners and will collaborate on cases where doing so is in the best interest of 
public health and safety. 
 
As the Board and staff move forward, they intend to continue monitoring and making quality 
improvements in the Investigation and processing of formal Complaints and Investigations. This 
allows the Board to make informed and expeditious decisions on the numerous Complaints that 
are received each year; all with the primary goal of protecting the health, safety and welfare of 
the public. 
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Appendix A:  Case Flow Diagram 
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Appendix B:  Formal Complaint Data 
 
Please see separate Excel spreadsheet data. 
13 
 
Appendix C:  Investigation Data 
 
Please see separate Excel spreadsheet data. 
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Appendix D:  Medication Error Data 
 
Please see separate Excel spreadsheet data. 
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Appendix E:  Investigation Status 
 
 
 
Status 2013 2014 2015 2016 2017 
Open 63 31 74 69 61 
Pending Board 52 50 26 42 43 
Pending Further Investigation 0 0 1 20 0 
Pending Legal 0 2 2 2 3 
Closed 76 136 144 211 195 
Total 191 219 247 344 302 
 
 
What this means:  The total number of active Investigations in 2017 decreased since 2016. This 
is still an increase from prior years.  Investigators continue to work diligently to obtain evidence, 
statements, and write Investigation reports to get the information to the Board as quickly as 
possible, resulting in a decrease of pending Investigations.  The Board is also consistently 
hearing most cases that are scheduled to be heard during each Board meeting. 
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Appendix F:  Investigation Dispositions 
 
 
 
 
 
Disposition 2013 2014 2015 2016 2017 
Resulting in Complaint 24 21 35 41 46 
Closed 43 109 109 170 195 
 
 
What this means:  Due to the increased volume of files processed in 2017 by investigators and 
the Board, both the total number of closed Investigations and Investigations resulting in, or 
associated with, a Complaint, increased slightly. 
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Appendix G:  Most Common Investigation Types 
 
  
Investigation Type 2013 2014 2015 2016 2017 
Regulatory Violation 18 27 31 71 90 
General Practice Standards 16 17 33 63 76 
Drug Violation 32 62 61 95 58 
Failure to Fill Rx Properly 28 28 21 17 27 
Inspectional Deficiencies 21 7 17 18 16 
Abnormal Report 0 0 40 37 13 
Other 27 52 19 19 6 
 
What this means:  The Board continued to see an increase in “Regulatory Violations” due to the 
self-reporting of continuing education deficiencies.  The increase in “General Practice 
Standards” is attributed to referrals by the Norfolk County District Attorney, related to the 
dispensing activities at 20 pharmacies that dispensed prescription drugs to patients that died of an 
overdose.  Investigators conducted robust Investigations to examine patient fill history, payment 
history, Drug Utilization Reviews, PMP data, and signed statements regarding the pharmacists’ 
corresponding responsibility.
 6
  Board staff also continued to monitor controlled substance loss 
reports, or “Drug Violations”.  The implementation of Policy 16-02, which extended time to 
report a loss of controlled substances, resulted in a decrease of these Investigations. 
                                                 
6
 M.G.L. 94C §19(a) states “The responsibility for the proper prescribing and dispensing of controlled substances 
shall be upon the prescribing practitioner, but a corresponding responsibility shall rest with the pharmacist who fills 
the prescription.” 
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Appendix H:  Other Investigation Types 
 
Investigation Type 2013 2014 2015 2016 2017 
Confidentiality Violation 1 1 2 5 4 
Criminal Activity 0 1 6 8 2 
Practice While Impaired 0 1 0 0 2 
Discipline in Another Jurisdiction 0 0 0 0 2 
SRE (Serious Reportable Event) 0 0 0 0 2 
Delay in Therapy 0 0 11 4 1 
Compounding Pharmacy OSR: Above Action Level 
EM 0 0 0 0 1 
Unlicensed Practice 0 0 0 0 1 
Unprofessional Conduct 8 7 3 2 1 
Practicing Beyond Scope 0 0 1 2 0 
Unethical Conduct 1 0 1 2 0 
Inadequate/Fraudulent Documentation 0 0 1 1 0 
Good Moral Character Evaluation 39 10 0 0 0 
Request for Inspection 1 0 0 0 0 
Substance Abuse 1 0 0 0 0 
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What this means:  The Board conducted a limited number of Investigations classified in the 
categories on the chart above. Most matters that are characterized in these categories are opened 
as Complaints, but these Investigations were opened to collect further information to determine if 
a Complaint is warranted.  In 2017, the Board also added a new Complaint type “Compounding 
Pharmacy OSR: Above Action Level EM” to monitor Out of Specification Reports as a result of 
Above Action Level Environmental Monitoring by sterile compounding pharmacies. 
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Appendix I:  Investigations by License Type 
 
 
 
 
Investigations by License Type 2013 2014 2015 2016 2017 
Drug Store 123 177 202 261 199 
Pharmacist 21 20 35 68 82 
Pharmacy Technician 10 11 5 9 12 
Nuclear Pharmacy 0 0 1 3 5 
Wholesale Distributor 1 2 3 2 3 
Pharmacy Intern 2 1 1 1 1 
Unlicensed 33 2 0 0 0 
 
 
What this means:  In keeping with historical figures, Drug Stores had the highest number of 
Investigations of all license types.  Investigations typically start against Drug Stores, as the Drug 
Store maintains and holds the records surrounding the alleged incidents.  Once information is 
obtained from the drug store in question and reviewed, related companion cases are opened 
against any individual licensees involved in the alleged incidents whose conduct constitutes a 
violation of applicable regulation or statute.  The rise in pharmacist Investigations is attributed to 
continuing education deficiency self-disclosures, as mentioned in Appendix G. 
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Appendix J:  Formal Complaint Statuses 
 
 
 
Status 2013 2014 2015 2016 2017 
Pending Investigation 55 42 45 84 36 
Pending Board Action 102 58 17 70 32 
Pending Board Counsel 84 126 64 31 24 
Pending Prosecution 48 42 43 30 26 
Pending Hearing Officer 0 4 1 9 5 
Pending Administrative Hold 0 0 0 1 0 
Closed 151 284 267 197 328 
Total 440 556 437 422 451 
 
What this means:  Most importantly, the 2017 data shows that the Board continued to process all 
Complaints that were waiting to be heard by the Board.  At the end of 2017, Complaints that are 
updated to Pending Board Action are routinely heard at the next scheduled Board meeting, 
unless they are delayed by extenuating circumstances beyond Board or staff control.  For 
example, many of the Complaints that have been Pending Board Action for longer than a month 
have not been heard due to lack of quorum caused by recusals.  In 2017, Complaint closure 
volume continued to rise as the backlogged Complaint volume from previous years complete the 
case flow process and newer Complaints are processed in the expedited formal Complaint 
processing system established in 2014. 
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Appendix K:  Formal Complaint Dispositions 
 
 
 
Disposition 2013 2014 2015 2016 2017 
Resulting in Discipline 51 74 74 70 108 
Resulting in Non-Discipline 26 78 83 13 37 
Dismissed 69 120 110 114 183 
 
What this means:  In keeping with the continued implementation of a Just Culture
7
, in 2017, 
licensees were given the opportunity to self-remediate human operator error Complaints related 
to medication errors by completing continuing education credits in anticipation of the Board 
hearing their respective Complaint.  This opportunity has resulted in many of the Complaints 
being dismissed for discipline not warranted, and a significant decrease in Complaints resulting 
in non-disciplinary action.  The increase in discipline is attributed to a large number of 
Complaints for inspectional deficiencies and drug violations resulting from record keeping 
discrepancies or diversion, which are areas that the Board is monitoring closely. 
                                                 
7
 A Just Culture recognizes that individual practitioners should not be held accountable for system failings over 
which they have no control.  A Just Culture also recognizes many individual or “active” errors represent predictable 
interactions between human operators and the systems in which they work.  However, in contrast to a culture that 
touts “no blame” as its governing principle, a Just Culture does not tolerate conscious disregard of clear risks to 
patients or gross misconduct (e.g., falsifying a record, performing professional duties while intoxicated).  Excerpted 
from: Marx D. Patient Safety and the “Just Culture”: A Primer for Health Care Executives.  New York, NY: 
Columbia University; 2001.  Available at: 
http://www.safer.healthcare.ucla.edu/safer/archive/ahrq/FinalPrimerDoc.pdf 
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Appendix L:  Most Common Complaint Types 
 
 
 
Complaint Type 2013 2014 2015 2016 2017 
Drug Violation 54 73 70 100 153 
Failure to Fill Rx Properly 162 229 142 128 140 
Inspectional Deficiencies 65 60 79 79 53 
Regulatory Violation 23 47 48 41 49 
Serious Reportable Event (SRE) 18 62 53 30 19 
General Practice Standards 52 27 18 16 16 
 
What this means:  In 2017, the most common Complaint type was “Drug Violation”.  Cases 
in this category often are the result of a reported loss of controlled substances, diversions or 
record keeping deficiencies.  In 2017, the Board opened Complaints on pharmacies that 
confirmed losses of drugs required to be on perpetual inventory.  Complaints for “Failure to 
Fill RX Properly,” showed a small increase.  The total number of Complaints in this category 
has significantly stabilized since 2014, when the Board began to process backlogged 
Complaints from previous years with new companion Complaints processed in 2014.  A 
continued and significant field presence in 2017 uncovered inspectional deficiencies and 
regulatory violations resulting in formal Complaints. 
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Appendix M:  Other Complaint Types 
 
 
 
Complaint Type 2013 2014 2015 2016 2017 
Criminal Activity 2 1 1 9 9 
DOR Notice 1 1 2 2 5 
Other 9 5 4 3 2 
Discipline in Another Jurisdiction 25 25 8 4 1 
Unethical Conduct 1 0 2 4 1 
Confidentiality Violation 5 4 2 2 1 
Practice While Impaired 1 1 0 0 1 
Unprofessional Conduct 2 0 0 0 1 
Unlicensed Practice 5 2 4 3 0 
Delay in Therapy 0 0 0 1 0 
Breach of Contract 3 3 2 0 0 
Abnormal Report 0 0 1 0 0 
Criminal Conviction 0 0 1 0 0 
General Misconduct 1 0 0 0 0 
Substance Abuse 1 0 0 0 0 
Summary Action 8 4 0 0 0 
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What this means:  In 2017, the total number of “Criminal Activity” Complaints remained the 
same.  However, the Board saw an increase in suspension notices from the Department of 
Revenue.  By law, the Board is required to suspend the license of the individual named after 
receiving such a notice from the Department of Revenue.  These Complaints are handled through 
an administrative process overseen by the Board’s Counsel. 
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Appendix N:  Complaints by License Type 
 
 
 
Complaints by License Type 2013 2014 2015 2016 2017 
Drug Store 151 195 194 203 237 
Pharmacist 176 238 165 133 133 
Pharmacy Technician 104 100 71 76 72 
Pharmacy Intern 3 9 5 6 4 
Wholesale Distributor 2 2 2 2 4 
Nuclear Pharmacy 0 0 0 1 1 
Unlicensed 2 1 0 1 0 
 
 
What this means:  In 2017, most Complaints opened by the Board were against Drug Stores.  As 
described in Appendix I for Investigations, Complaints also typically begin with Drug Stores and 
after additional information is received, related companion cases are opened against individual 
licensees involved in the alleged incident(s).  The rise in Drug Store Complaint volume is 
attributed to drug violation and medication error Complaints opened in 2017.  Complaint volume 
for pharmacists remained consistent with 2016 volume.  Complaint volume for all other license 
types decreased in 2017. 
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Appendix O:  Collaboration with Outside Agencies 
 
 
 
 
Collaboration with Outside Agencies 2013 2014 2015 2016 2017 
Complaints 42 60 49 67 77 
Investigations 20 26 16 25 38 
 
 
What this means:  In 2017, the data demonstrates a significant increase in Complaints and 
Investigations where staff continued to collaborate with outside agencies.  The Board and Board 
staff continue to forge strong relationships with our local, state and federal partners and will 
collaborate on cases where doing so is in the best interest of public health and safety. 
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Appendix P:  Case Openings 
 
 
 
 
 
 
 
 
 
What this means:  In 2017, Complaint openings remained steady, while Investigation openings 
decreased.  This is attributed to the implementation of Policy 16-02, which extended time to 
report a loss of controlled substances, resulting in these matters remaining triage files until the 
loss is confirmed or located prior to the close of the reporting timeframe. 
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Appendix Q:  Case Closings 
 
 
 
 
 
 
 
 
 
 
 
What this means:  Overall, in 2017, the Board has achieved a 130.4% increase since 2013 in 
Complaint and Investigation closings.  Furthermore, in 2017, the Board closed 99 more cases 
than in 2016.  Investigators and Board staff continue to work diligently to conduct Investigations 
and process cases expeditiously. 
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